New blood test to detect the presence of clinically significant prostate cancer launched

A new blood test that determines whether a man does or does not have prostate cancer that requires treatment – clinically significant prostate cancer – has been launched in the UK. The Mitomic Prostate Test (MPT) takes advantage of the unique characteristics of mutations in mitochondrial DNA as biomarkers which can signify the presence of clinically significant prostate cancer. A clinical study carried out in collaboration with the University of Cambridge shows that the MPT biomarker has a higher than 99% negative predictive value. This means that men with a negative MPT result can therefore safely delay or avoid further diagnostic tests, as they